The 36-month beta value for JSPR is at 2.74. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JSPR is 12.59M, and currently, shorts hold a 12.25% of that float. The average trading volume for JSPR on July 03, 2025 was 242.85K shares.
JSPR) stock’s latest price update
Jasper Therapeutics Inc (NASDAQ: JSPR)’s stock price has increased by 18.82% compared to its previous closing price of $5.74. However, the company has seen a 22.55% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-14 that 11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif.
JSPR’s Market Performance
JSPR’s stock has risen by 22.55% in the past week, with a monthly rise of 25.14% and a quarterly rise of 64.73%. The volatility ratio for the week is 10.78% while the volatility levels for the last 30 days are 8.95% for Jasper Therapeutics Inc The simple moving average for the last 20 days is 20.52% for JSPR stock, with a simple moving average of -40.87% for the last 200 days.
Analysts’ Opinion of JSPR
Many brokerage firms have already submitted their reports for JSPR stocks, with UBS repeating the rating for JSPR by listing it as a “Buy.” The predicted price for JSPR in the upcoming period, according to UBS is $38 based on the research report published on February 13, 2025 of the current year 2025.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see JSPR reach a price target of $63. The rating they have provided for JSPR stocks is “Outperform” according to the report published on December 06th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to JSPR, setting the target price at $70 in the report published on September 09th of the previous year.
JSPR Trading at 29.99% from the 50-Day Moving Average
After a stumble in the market that brought JSPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.82% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JSPR starting from Mahal Jeetinder Singh, who sale 900 shares at the price of $22.11 back on Dec 12 ’24. After this action, Mahal Jeetinder Singh now owns 25,009 shares of Jasper Therapeutics Inc, valued at $19,899 using the latest closing price.
Stock Fundamentals for JSPR
Current profitability levels for the company are sitting at:
- -70.67 for the present operating margin
- 0.25 for the gross margin
The net margin for Jasper Therapeutics Inc stands at 11.69. The total capital return value is set at -1.83. Equity return is now at value -101.34, with -85.84 for asset returns.
Based on Jasper Therapeutics Inc (JSPR), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -26.91. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -16.4.
Currently, EBITDA for the company is -71.39 million with net debt to EBITDA at 4.21. When we switch over and look at the enterprise to sales, we see a ratio of 47.91. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.31.
Conclusion
In conclusion, Jasper Therapeutics Inc (JSPR) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
